Published in:
Open Access
01-12-2014 | Original investigation
Possible effects of glimepiride beyond glycemic control in patients with type 2 diabetes: a preliminary report
Authors:
Ikuko Nakamura, Jun-ichi Oyama, Hiroshi Komoda, Aya Shiraki, Yoshiko Sakamoto, Isao Taguchi, Atsushi Hiwatashi, Aiko Komatsu, Masayoshi Takeuchi, Sho-ichi Yamagishi, Teruo Inoue, Koichi Node
Published in:
Cardiovascular Diabetology
|
Issue 1/2014
Login to get access
Abstract
Background
The purpose of this study was to elucidate the effects of glimepiride on the levels of biomarkers related to cardiovascular regulation in patients with type 2 diabetes mellitus.
Methods and results
Thirty-four patients with type 2 diabetes received glimepiride for 24 weeks. Significant decreases in the levels of glyceraldehyde-derived advanced glycation end products, (glycer-AGE: toxic AGE), eotaxin and fibroblast growth factor (FGF)-2 were recognized after the administration of glimepiride. Moreover, there were trends for there to be increases in the levels of granulocyte-colony stimulating factor (G-CSF) and granulocyte macrophage-colony stimulating factor (GM-CSF), and decreases in the levels of fractalkine, soluble CD40 ligand (sCD40L), macrophage inflammatory protein (MIP)-β, vascular endothelial growth factor (VEGF) and soluble receptor for AGE (sRAGE).
Conclusions
Glimepiride may have potent anti-oxidative, anti-inflammatory and angiogenic properties and it may potentially repair tissue damage by decreasing the levels of toxic AGE and increasing colony-stimulating factors.